Focused On-demand Library for Tyrosine-protein phosphatase non-receptor type 2

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

P17706

UPID:

PTN2_HUMAN

Alternative names:

T-cell protein-tyrosine phosphatase

Alternative UPACC:

P17706; A8K955; A8MXU3; K7ENG3; Q96AU5; Q96HR2

Background:

Tyrosine-protein phosphatase non-receptor type 2, also known as T-cell protein-tyrosine phosphatase, plays a pivotal role in dephosphorylating receptor and non-receptor protein tyrosine kinases. It is crucial in regulating signaling pathways that influence cell proliferation, differentiation, immune system development, and glucose homeostasis. Its activity affects various cytokine-mediated signaling, impacting inflammatory responses and T-cell activation.

Therapeutic significance:

Understanding the role of Tyrosine-protein phosphatase non-receptor type 2 could open doors to potential therapeutic strategies. Its involvement in key biological processes and signaling pathways suggests its potential as a target in treating diseases related to immune system dysfunction, metabolic disorders, and certain cancers.